⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TGTX News
TG Therapeutics, Inc.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
globenewswire.com
TGTX
Tangram Therapeutics annonce l’administration de la première dose à un participant dans le cadre de l’essai RESTORE-MASH de phase I/II portant sur le TGM-312, un nouveau médicament expérimental à base d’ARNi
globenewswire.com
TGTX
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
businesswire.com
DTIL
TGTX
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
businesswire.com
TGTX
DTIL
Form 8-K
sec.gov
TGTX
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
globenewswire.com
TGTX
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
globenewswire.com
TGTX
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
globenewswire.com
TGTX
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
globenewswire.com
TGTX
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
globenewswire.com
TGTX